Business

Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

New Director Brings Extensive Experience to Poise the Company for Growth MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a

articleNeuronetics, Inc.December 29, 20224/company/neuronetics-inc/news/neuronetics-announces-appointment-of-joseph-h-capper-to-its-board-of-directors
Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

About this update from Neuronetics, Inc.

[{"type":"text","content":"New Director Brings Extensive Experience to Poise the Company for Growth\nMALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. “Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals,\" said Rob Cascella, Chairman of the Board of Neuronetics. “His depth of experience with public companies and his passion for innovative medical technologies will further strengthen our Board, benefit our company, and help the patients served by our mental health providers.” Mr. Capper brings nearly 30 years of med-tech and life sciences experience to the Company. Most recently, he served as President and Chief Executive Officer of BioTelemetry, Inc, (formerly Nasdaq: BEAT), the successor to CardioNet, Inc., and Home Diagnostics, Inc. (Nasdaq: HDIX). Prior to Home Diagnostics, Joe was President and Chief Executive Officer of CCS Medical Inc., a private company. Earlier, Joe spent nine years with Bayer Corporation, ultimately becoming National Sales Director of the Diabetic Products Division. Joe also has a distinguished service record, having served in the U.S. Navy as a combat aviator and later as a congressional liaison. Joe received his undergraduate degree in accounting from West Chester University and an MBA in International Finance from George Washington University. “The accelerating decline of mental health in the wake of the pandemic makes Neuronetics’ technology more relevant than ever,” said Mr. Capper. “I am impressed by the organization’s mission to transform neurohealth and its passion for that purpose. I look forward to contributing to the company’s future success.” About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering ...

More updates from Neuronetics, Inc.